Abstracts tagged "gout"

Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
Abstract Number: 1112 • 2017 ACR/ARHP Annual Meeting
Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout
Rochella A. Ostrowski¹, Elizabeth Araujo², Richard Hariman³ and Elaine Adams⁴, ¹Division of Rheumatology, Loyola University Medical Center, Maywood, IL, ²Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Rheumatology, Edward Hines Jr Hospital, Veterans Administration, Hines, IL
Background/Purpose: Despite the use of corticosteroids in acute gout, there exist wide variations in treatment doses and duration. No studies have evaluated the ideal dose…
Abstract Number: 2059 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
An-Chen Fu, Douglas C.A. Taylor and David S. Reasner, Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Allopurinol is a first-line urate-lowering therapy…
Abstract Number: 2250 • 2017 ACR/ARHP Annual Meeting
Linguistic Differences in Gout-Related Online Content: A Comparison of Professional Health Literature for Consumers Vs Patients’ Online Discussions of Gout
W. Benjamin Nowell¹, Kayla Jordan², Kelly Gavigan¹, Louis Tharp¹, Jeffrey R. Curtis³ and James Pennebaker⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²University of Texas at Austin, Austin, TX, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Psychology, University of Texas at Austin, Austin, TX
Background/Purpose: Non-adherence to gout medication is high. This may be due in part to patients’ belief that gout is primarily caused by overindulgence in certain…
Abstract Number: 1116 • 2017 ACR/ARHP Annual Meeting
Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction
Dawen Zhang¹, Kichul Ko², Michael A. Becker² and Reem Jan¹, ¹Medicine, Rheumatology, University of Chicago, Chicago, IL, ²Medicine, University of Chicago, Chicago, IL
Background/Purpose: Patients with gout frequently have multiple serious co-morbidities, take concomitant medications, and have complex clinical profiles, making treatment of acute flares in hospital settings…
Abstract Number: 2062 • 2017 ACR/ARHP Annual Meeting
Flow-Mediated Dilation As a Marker of Endothelial Dysfunction in Gout
Enrique Calvo Aranda¹, Ofelia Carrion², Afnan Abdelkader², Jorge Juan González Martín³, Francisco Aramburu³, Marta Valero⁴, Silvia Rodriguez⁴, Carolina Marin³, Irene Amil³, Felipe Sainz⁵ and Paloma Garcia De La Peña³, ¹RHEUMATOLOGY, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ²Vascular Surgery Department, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ³Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ⁴Rheumatology, Hospital Madrid Norte Sanchinarro, MADRID, Spain, ⁵Vascular Surgery, Hospital Madrid Norte Sanchinarro, MADRID, Spain
Background/Purpose: Several studies have shown the relationship between gout and increased cardiovascular risk and mortality. Hyperuricemia and crystal-induced synovitis are associated with endothelial dysfunction and…
Abstract Number: 2265 • 2017 ACR/ARHP Annual Meeting
Survey on Gout-Related Knowledge and Perception in Inpatient Setting on Hospitalized Patients with Gout
Roshanak Habibi¹, David T Liss², Sreelakshmi Panginikkod¹, Alvaro Altamirano Ufion³, Ehsan Rajabirostami¹ and Manish Jain⁴, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Northwestern University, Chicago, IL, ³Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, ⁴Rheumatology, Presence Saint Francis Hospital, Evanston, IL
Background/Purpose: The increasing global burden of gout disease and its impact on the patient’s quality of life calls for new strategies in management. Even though…
Abstract Number: 1117 • 2017 ACR/ARHP Annual Meeting
the Absolute Risk of Clinically Diagnosed Gout By Serum Uric Acid Levels – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Meliha C. Kapetanovic¹, Peter M Nilsson², Carl Turesson³, Martin Englund⁴, Nicola Dalbeth⁵, Lieke E.J.M. Scheepers⁶ and Lennart TH Jacobsson⁶, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Sweden., Lund, Sweden, ³Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁴Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁵University of Auckland, Auckland, New Zealand, ⁶Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Hyperuricemia i.e. increased s-uric acid levels (s-UA), is established risk factor for clinical gout. Studies regarding the absolute and relative effect on population level…
Abstract Number: 2063 • 2017 ACR/ARHP Annual Meeting
Relation of Serum Urate and Gout Duration to Tophi, Urate Deposition, and Inflammation
Ana Beatriz Vargas-Santos¹, S. Reza Jafarzadeh², Geraldo Castelar-Pinheiro¹, Nicola Dalbeth³, William J. Taylor⁴, Jaap Fransen⁵, Tim L. Jansen⁶, H. Ralph Schumacher⁷ and Tuhina Neogi², ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³University of Auckland, Auckland, New Zealand, ⁴Department of Medicine, University of Otago, Wellington, New Zealand, ⁵Department of Rheumatolgy, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁷Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: Gout duration and serum urate (SU) levels are thought to influence development of tophi and chronic inflammatory gouty arthropathy, but the extent to which…
Abstract Number: 2847 • 2017 ACR/ARHP Annual Meeting
The Sons of Gout Study. Ultrasonographic Evaluation of Asymptomatic Monosodium Urate Crystal Deposition in Sons of People with Gout
Abhishek Abhishek¹, Wendy Jenkins¹, Philip Courtney², Adrian Jones³, Weiya Zhang⁴ and Michael Doherty⁵, ¹Devision of Rheumatology, University of Nottingham, NG5 1PB, England, ²Department of Rheumatology, Notingham, United Kingdom, ³Rheumatology Unit, Nottingham City Hospital, Nottingham Notts, United Kingdom, ⁴Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, United Kingdom, ⁵Academic Rheumatology, University of Nottingham, Nottingham, Great Britain
Background/Purpose: Hyperuricemia and gout aggregate in families. The objectives of this study were to estimate the prevalence of asymptomatic monosodium urate (MSU) crystal deposition in…
Abstract Number: 1119 • 2017 ACR/ARHP Annual Meeting
Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US
Robert Morlock¹, Pierre Chevalier², An-Chen Fu³ and Douglas C.A. Taylor³, ¹YourCareChoice, Ann Arbor, MI, ²IMS Health, Zaventem, Belgium, ³Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Elevated sUA is associated with worsened…
Abstract Number: 2064 • 2017 ACR/ARHP Annual Meeting
The Nomenclature of Gout: A Content Analysis of Contemporary Medical Journals
David Bursill^1,2, William J. Taylor³, Robert Terkeltaub⁴ and Nicola Dalbeth⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²School of Medicine, University of Adelaide, Adelaide, Australia, ³University of Otago, Wellington, New Zealand, ⁴Rheumatology, VA San Diego Healthcare System, San Diego, CA, ⁵University of Auckland, Auckland, New Zealand
Background/Purpose: Gout has been recognized and described since antiquity. However, the terms used to describe the disease lack standardization. The aim of this study was…
Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting
Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study
Ted R. Mikuls¹, TC Cheetham², Gerald D. Levy³, Nazia Rashid⁴, Kimberly Low⁵, Brian W Coburn⁶, Kenneth Saag⁷, Lang Chen⁸ and Jeffrey R. Curtis⁹, ¹Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ³Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, ⁵Kaiser Permanente Southern California, Panorama City, CA, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Allopurinol is a cornerstone therapy in gout management. Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
Abstract Number: 1120 • 2017 ACR/ARHP Annual Meeting
Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target
Robert Morlock¹, Douglas C.A. Taylor² and Scott Baumgartner³, ¹YourCareChoice, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³drB Consulting, Spokane, WA
Background/Purpose: Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients…
Abstract Number: 2070 • 2017 ACR/ARHP Annual Meeting
Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout
Naomi Schlesinger¹, Puja Khanna², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: A Delphi exercise reached consensus on a definition for gout remission that included serum uric acid (sUA) <6 mg/dL, no flares, resolution of all…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].